Method Of Regulating Cell Metabolism Or Physiology Patents (Class 435/375)
-
Patent number: 11781108Abstract: The present invention provides a method with which it is possible to directly induce nervous system cells efficiently and in a short amount of time. Because the method is easy to scale up and is not affected by the characteristics or background of the somatic cells used as material, the method enables the stable supply of nervous system cells. The nervous system cells obtained by the method are useful in various fields of research and healthcare.Type: GrantFiled: January 18, 2016Date of Patent: October 10, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, KATAOKA CORPORATIONInventors: Ping Dai, Tetsuro Takamatsu
-
Patent number: 11773084Abstract: The 4-arylamino-2-(6-indolylamino)pyrimidine derivative compounds are antibacterial agents having broad spectrum antibacterial activity. The present 4-arylamino-2-(6-indolylamino)pyrimidine compounds have antimicrobial activity against various susceptible and resistant gram-positive and gram-negative bacteria as well as drug resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: April 14, 2023Date of Patent: October 3, 2023Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11769597Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.Type: GrantFiled: June 1, 2018Date of Patent: September 26, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lorah Perlee, Sara Hamon, Charles Paulding
-
Patent number: 11767558Abstract: Polynucleotide sequencing methods include incubating unlabeled nucleotides with a cluster of template polynucleotide strands having the same sequence when the identity of the previously added labeled nucleotide is being detected. The detection step provides time for the addition of the unlabeled nucleotides to be incorporated into the copy strands in which the previously added labeled nucleotide did not get incorporated. Thus, at the end of the detection step, all or most of the copy strands will be in phase and ready to incorporate the appropriate labeled nucleotide in the subsequence incorporate step.Type: GrantFiled: December 5, 2019Date of Patent: September 26, 2023Assignee: Illumina Cambridge LimitedInventors: Pietro Gatti-Lafranconi, Philip Balding
-
Patent number: 11767531Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.Type: GrantFiled: May 18, 2022Date of Patent: September 26, 2023Assignee: MPEG LA, LLCInventors: Philipp Hadwiger, Hans-Peter Vornlocher, Jonathan Miles Brown, James Everett Dahlman, Kristin K. H. Neuman
-
Patent number: 11766478Abstract: Described herein are methods comprising administering to a mammalian subject an effective amount of an annexin chimeric fusion protein, wherein the annexin chimeric fusion protein comprises at least one immunogenic antigen, thereby enhancing the antigen specific immune response relative to administration of the immunogenic antigen alone. Methods and kits for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer, are described. A method may comprise priming a mammal by administering to the mammal an effective amount of a chemotherapeutic agent and boosting the mammal by administering to the mammal an effective amount of an annexin chimeric fusion.Type: GrantFiled: August 28, 2020Date of Patent: September 26, 2023Assignee: The Johns Hopkins UniversityInventors: Tzyy-Choou Wu, Chien-Fu Hung
-
Patent number: 11760976Abstract: Methods and products obtained from the method for isolating and culturing mixed populations of stem cells, making decellularized tissue matrix, making decellularized tissue matrix infused with said mixed populations of stem cells, and methods of stem cell therapy are provided.Type: GrantFiled: October 27, 2020Date of Patent: September 19, 2023Assignee: STEM CELL RESERVE, LPInventor: Raymond Mouzannar
-
Patent number: 11753624Abstract: The various embodiments of the disclosure relate generally to processes, methods, and systems for generating functional B cells ex vivo. It is particularly useful for ex vivo generation of antigen-specific germinal-center (GC) like B cells that are capable of efficient B cell expansion, immunoglobulin (Ig) class switching/class switching recombination (CSR), expression of germinal B cell phenotypes, antibody secretion, and somatic hypermutation (SHM) and resulting affinity maturation center phenotypes.Type: GrantFiled: October 6, 2016Date of Patent: September 12, 2023Assignee: Georgia Tech Research CorporationInventors: Krishnendu Roy, Kyung-Ho Roh
-
Patent number: 11753454Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.Type: GrantFiled: October 12, 2020Date of Patent: September 12, 2023Assignees: Cytune Pharma, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
-
Patent number: 11752238Abstract: Disclosed are compositions and related methods of recapitulating bone marrow stroma using scaffold materials (e.g., a porous alginate hydrogel scaffold) containing one or more cellular differentiation factors, and one or more growth factors. Such methods and compositions promote the formation of an ectopic nodule or site that can improve transplanted cell engraftment and selectively drive the development of lymphocytes and the reconstitution of the adaptive immunity after hematopoietic stem cell transplant.Type: GrantFiled: February 6, 2017Date of Patent: September 12, 2023Assignees: President and Fellows of Harvard College, The General Hospital CorporationInventors: Nisarg J. Shah, Ting-Yu Shih, Angelo Mao, David J. Mooney, David T. Scadden
-
Patent number: 11738046Abstract: An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.Type: GrantFiled: November 2, 2018Date of Patent: August 29, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Peiman Hematti, Connie Chamberlain, Anna Elizabeth Breiner Clements, Ray Vanderby, John A. Kink
-
Patent number: 11739330Abstract: In some aspects, the disclosure relates to compositions and methods useful for inhibiting SOD1 expression in cells (e.g., cells of a subject). In some embodiments, the disclosure describes isolated nucleic acids engineered to express an inhibitory nucleic acid targeting endogenous SOD1 and an mRNA encoding a hardened SOD1 protein. In some embodiments, compositions and methods described by the disclosure are useful for treating Amyotrophic Lateral Sclerosis (ALS) in a subject.Type: GrantFiled: September 21, 2018Date of Patent: August 29, 2023Assignee: University of MassachusettsInventors: Christian Mueller, Robert H. Brown
-
Patent number: 11739335Abstract: The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.Type: GrantFiled: March 23, 2018Date of Patent: August 29, 2023Assignee: CureVac SEInventors: Frédéric Chevessier-Tünnesen, Marion Poenisch, Thomas Schlake
-
Patent number: 11730726Abstract: Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.Type: GrantFiled: July 11, 2019Date of Patent: August 22, 2023Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Pearlie Burnette, Nicholas J. Lawrence, Harshani Lawrence
-
Patent number: 11726101Abstract: An in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay containing two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions contains at least 4 or 5 amino acids, and further assays and calibration methods.Type: GrantFiled: June 16, 2021Date of Patent: August 15, 2023Assignee: SPHINGOTEC GMBHInventor: Andreas Bergmann
-
Patent number: 11725204Abstract: Compositions and methods for gene editing are provided. The methods employ an oligo-based annealing mechanism that is rooted in the process of DNA replication rather than homologous recombination (HR). Oligo incorporation efficiencies are comparable and often exceed those of CRISPR/cas9 editing without the need for double strand breaks (DSBs). By relying on the multiplex annealing of oligos rather than DSBs the process is highly scalable across a genomic region of interest and can generate many scarless modifications of a chromosome simultaneously. Combinatorial genomic diversity can be generated across a population of cells in a single transformation event; genomic landscapes can be traversed through successive iterations of the process, and genome-wide changes can be massively parallelized and amplified through systematic strain mating.Type: GrantFiled: April 27, 2017Date of Patent: August 15, 2023Assignee: YALE UNIVERSITYInventors: Edward Barbieri, Farren Isaacs
-
Patent number: 11717480Abstract: Extracellular vesicles, their manufacture, and methods of treatment are described. Generally, extracellular vesicles can be generated by applying sulfhydryl blocking reagents on animal cells. Extracellular vesicles can be loaded with compounds for an intended use, such as, for example, loading an extracellular vesicle with a medicament to treat an animal. As described here, extracellular vesicles can be generated in a large scale and used for personalized treatments.Type: GrantFiled: November 30, 2017Date of Patent: August 8, 2023Assignee: The Regents of the University of CaliforniaInventors: Young Jik Kwon, Dominique Antoinette Ingato
-
Patent number: 11713345Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.Type: GrantFiled: October 22, 2019Date of Patent: August 1, 2023Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Shannon Mullican, Matthew M. Rankin, Xiefan Lin-Schmidt, Chichi Huang, Jennifer Furman, Songmao Zheng, Shamina Rangwala, Serena Nelson
-
Patent number: 11712477Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.Type: GrantFiled: March 17, 2020Date of Patent: August 1, 2023Assignee: NexImmune, Inc.Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
-
Patent number: 11708421Abstract: A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.Type: GrantFiled: July 18, 2017Date of Patent: July 25, 2023Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ranit Kedmi, Nuphar Veiga, Itai Benhar, Dan Peer
-
Patent number: 11702402Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety (e.g., RA190) that is a binder of the ubiquitin receptor RPN13 to induce degradation of RPN13 and thereby inhibit proteasome function. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, cancers, benign neoplasms, pathological angiogenesis, inflammatory diseases, and autoimmune diseases). Provided also are methods of inducing the degradation of ubiquitin receptor RPN13 by administering a bifunctional compound or composition described herein, wherein one component of the bifunctional compound is a binder of an E3 ubiquitin ligase (e.g., lenalidomide, thalidomide) and another component of the compound is a binder of ubiquitin receptor RPN13 (e.g., RA190) in a subject.Type: GrantFiled: February 22, 2019Date of Patent: July 18, 2023Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Jun Qi, Kenneth C. Anderson, Lei Wu, Yan Song, Dharminder Chauhan
-
Patent number: 11696938Abstract: Provided are a novel agent for inhibiting metastasis of human cancer cells, and a novel agent for determining whether target cells are cancer cells or not in a human. A human cancer cell metastasis inhibitor including human dicalcin or a partial peptide thereof, and a human cancer cell determination agent including human dicalcin or a partial peptide thereof.Type: GrantFiled: September 26, 2018Date of Patent: July 11, 2023Inventors: Naofumi Miwa, Mayu Aoyama
-
Patent number: 11696899Abstract: Oral compositions comprising cinnamaldehyde, and methods or improving circulation and improving circulation by administering such compositions, are described. Methods and uses are describe that include the administration of an effective amount of the oral compositions to improve circulation and increasing nerve sensitization, while also resulting in improved balance, and reduced pain, numbness, and/or tingling in the hands and feet, as well as reduced restlessness, fatigue, and tiredness of the legs.Type: GrantFiled: December 29, 2020Date of Patent: July 11, 2023Assignee: INNOVUS PHARMACEUTICALS, INC.Inventor: Bassam Damaj
-
Patent number: 11697808Abstract: Engineered Streptococcus canis Cas9 (ScCas9) variants include an ScCas9 protein with its PID being the PID amino acid composition of Streptococcus pyogenes Cas9 (SpCas9)-NG, an ScCas9 protein having a threonine-to-lysine substitution mutation at position 1227 in its amino acid sequence (Sc+), and an ScCas9 protein having a threonine-to-lysine substitution mutation at position 1227 and a substitution of residues ADKKLRKRSGKLATE [SEQ ID No. 4] in position 365-379 in the ScCas9 open reading frame (Sc++). Also included are CRISPR-associated DNA endonucleases with a PAM specificity of 5?-NG-3? or 5?-NNG-3? and a method of altering expression of a gene product by utilizing the engineered ScCas9 variants.Type: GrantFiled: June 30, 2022Date of Patent: July 11, 2023Assignee: Massachusetts Institute of TechnologyInventors: Pranam Chatterjee, Noah Michael Jakimo, Joseph M. Jacobson
-
Patent number: 11690920Abstract: The present disclosure generally relates to metal-organic framework nanoparticles containing terminal phosphate-modified oligonucleotides, methods for making the same, and methods of using the same.Type: GrantFiled: July 13, 2018Date of Patent: July 4, 2023Assignee: NORTHWESTERN UNIVERSITYInventors: Chad A. Mirkin, Shunzhi Wang
-
Patent number: 11685888Abstract: A method for producing a product related to the specified technology includes adjusting the concentration of cells in a culture vessel to a value of from 3×107 cells/ml to 3×108 cells/ml; in a case in which the average diameter of single cells in the culture vessel is designated as A, adjusting the number proportion of cells having a single cell diameter of 1.4×A or greater in the culture vessel to 5% or less, and adjusting the number proportion of cells having a single cell diameter in the range of A±A/7 to 50% or more.Type: GrantFiled: March 3, 2020Date of Patent: June 27, 2023Assignee: FUJIFILM CorporationInventors: Shinichi Nakai, Naoto Takahashi
-
Patent number: 11680090Abstract: The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.Type: GrantFiled: August 12, 2020Date of Patent: June 20, 2023Assignee: Medicenna Therapeutics, Inc.Inventor: Fahar Merchant
-
Patent number: 11680079Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.Type: GrantFiled: April 13, 2020Date of Patent: June 20, 2023Assignees: University of Iowa Research Foundation, The United States Government As Represented By The Department of Veteran AffairsInventors: Paloma H. Giangrande, Francis Miller, Kevin Urak
-
Patent number: 11672851Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.Type: GrantFiled: December 1, 2020Date of Patent: June 13, 2023Assignees: RIKEN, ASTELLAS PHARMA INC.Inventors: Ayaka Akiba, Tatsuya Okudaira, Yasuhide Masuhara, Keisuke Ohsumi, Shinichiro Fujii
-
Patent number: 11676687Abstract: Systems and methods are provided for tracking the provenance of genetic material using blockchain-based technologies. Immutable records of transactions associated with the genetic material are generated. These records can be utilized to create an audit trail for the genetic material.Type: GrantFiled: May 18, 2021Date of Patent: June 13, 2023Assignee: EGGSCHAIN, INC.Inventor: Wei Escala
-
Patent number: 11667663Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: August 30, 2018Date of Patent: June 6, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Xiao Zhu
-
Patent number: 11666596Abstract: Provided are applications of an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a polypeptide coded by the same. A potential ORF of 96 bases (31aa-uORF) existing in the 5? UTR of the PTEN can code an oligopeptide of 31 amino acids (named PTEN-31aa) and plays an important role in the development and progression process of tumors. Provided is a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular gliomas. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.Type: GrantFiled: June 8, 2018Date of Patent: June 6, 2023Assignee: THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITYInventor: Nu Zhang
-
Patent number: 11667914Abstract: Provided herein are chemically ligated guide RNA oligonucleotides (lgRNA) which comprise two functional RNA modules (crgRNA and tracrgRNA) joined by non-nucleotide chemical linkers (nNt-linker), their complexes with CRISPR-Cas9, preparation methods of Cas9-lgRNA complexes, and their uses for prevention and treatments of herpesvirus infections in humans. Also disclosed are processes and methods for preparation of these compounds.Type: GrantFiled: July 9, 2018Date of Patent: June 6, 2023Inventor: Minghong Zhong
-
Patent number: 11661423Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: GrantFiled: October 20, 2020Date of Patent: May 30, 2023Assignee: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 11661590Abstract: Some aspects of this disclosure provide a fusion protein comprising a guide nucleotide sequence-programmable DNA binding protein domain (e.g., a nuclease-inactive variant of Cas9 such as dCas9), an optional linker, and a recombinase catalytic domain (e.g., a tyrosine recombinase catalytic domain or a serine recombinase catalytic domain such as a Gin recombinase catalytic domain). This fusion protein can recombine DNA sites containing a minimal recombinase core site flanked by guide RNA-specified sequences. The instant disclosure represents a step toward programmable, scarless genome editing in unmodified cells that is independent of endogenous cellular machinery or cell state.Type: GrantFiled: August 9, 2017Date of Patent: May 30, 2023Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, Brian Chaikind, Jeffrey L. Bessen
-
Patent number: 11655474Abstract: Disclosed are means, methods and compositions of matter useful for suppressing pathological production of new blood vessels in conditions such as cancer and wet macular degeneration. In one embodiment the invention provides silencing of NR2F6 using nucleic acid based approaches such as RNA interference, antisense oligonucleotides, or DICER. In another embodiment, the invention teaches the administration of small molecule NR2F6 inhibitors as means of selectively inhibiting pathological but not healthy angiogenesis.Type: GrantFiled: November 2, 2020Date of Patent: May 23, 2023Assignee: Regen Biopharma, Inc.Inventors: Thomas Ichim, David Koos
-
Patent number: 11648223Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.Type: GrantFiled: March 3, 2022Date of Patent: May 16, 2023Assignee: Io Therapeutics, Inc.Inventors: Roshantha A. Chandraratna, Martin E. Sanders
-
Patent number: 11639530Abstract: The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.Type: GrantFiled: April 14, 2020Date of Patent: May 2, 2023Assignee: Korea University Research and Business FoundationInventors: Je Sang Ko, Min-Soo Kang
-
Patent number: 11629167Abstract: The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.Type: GrantFiled: November 9, 2018Date of Patent: April 18, 2023Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: George R. Pettit, Noeleen Melody
-
Patent number: 11623963Abstract: A specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein numbering is according to the IMGT, and wherein the antibody Fc region does not comprise an antigen-binding CH3 domain; and an ABM conjugate (ABMC) comprising the ABM and at least one heterologous molecule covalently conjugated to one or both of the cysteines at positions 108 and 113 of the CH2 domain.Type: GrantFiled: October 3, 2018Date of Patent: April 11, 2023Assignee: MERCK PATENT GMBHInventors: Gordana Wozniak-Knopp, Florian Rüker, Gerhard Stadlmayr, Jakub Rybka, Nicolas Rasche, Stephan Dickgiesser
-
Patent number: 11613730Abstract: The present invention relates to a method for culturing natural killer cells (NK cells) applied to immune therapy and, more particularly, to a medium addition kin for culturing NK cells with which lymphocytes derived from human peripheral blood can be cultured to effectively amplify and activate NK cells, which have an outstanding therapeutic effect on malignant tumors, while remarkably increasing the share of NK cells, and an NK cell culturing method using the kit.Type: GrantFiled: August 15, 2018Date of Patent: March 28, 2023Assignees: NKCL BIO GROUP INC.Inventor: Dong Hyuk Shin
-
Patent number: 11591595Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.Type: GrantFiled: August 6, 2020Date of Patent: February 28, 2023Assignee: Biogen MA Inc.Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
-
Patent number: 11581060Abstract: The present disclosure provides for systems and methods for generating and displaying a three dimensional map of a protein sequence. An exemplary method can provide for using deep learning models to predict protein folding and model protein folding using three dimensional representations. The method more effectively exploits the potential of deep learning approaches. The method approach overall involves three stages—computation, geometry, and assessment.Type: GrantFiled: January 6, 2020Date of Patent: February 14, 2023Assignee: President and Fellows of Harvard CollegeInventor: Mohammed AlQuraishi
-
Patent number: 11578325Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.Type: GrantFiled: May 23, 2019Date of Patent: February 14, 2023Inventor: David Berz
-
Patent number: 11578101Abstract: Unique compounds useful for inhibiting a proteasome in a cell, pharmaceutical compositions and methods of their use are provided herein.Type: GrantFiled: August 6, 2019Date of Patent: February 14, 2023Assignee: University of Kentucky Research FoundationInventor: Kyung Bo Kim
-
Patent number: 11566253Abstract: The present disclosure relates to the use of recombinant proteins for inducing epigenetic modifications at specific loci, as well as to methods of using these recombinant proteins for modulating the expression of genes in plants.Type: GrantFiled: January 22, 2018Date of Patent: January 31, 2023Assignee: The Regents of the University of CaliforniaInventors: Steve E. Jacobsen, Javier Gallego-Bartolomé, Ashot Papikian, Jason Gardiner
-
Patent number: 11561225Abstract: The present invention relates to compositions and methods for the prevention or the treatment of lung cancer, wherein the compositions comprise an antibody binding to progastrin and the methods comprise the use of an antibody binding to progastrin.Type: GrantFiled: March 30, 2018Date of Patent: January 24, 2023Assignee: Progastrine et Cancers S.à r.l.Inventor: Alexandre Prieur
-
Patent number: 11535863Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.Type: GrantFiled: June 13, 2019Date of Patent: December 27, 2022Assignee: President and Fellows of Harvard CollegeInventors: George M. Church, Prashant G. Mali, Luhan Yang
-
Patent number: 11529350Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X1, X2, R2, R3, R4, R5, R6, R7, R8, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.Type: GrantFiled: July 2, 2020Date of Patent: December 20, 2022Assignee: Sumitomo Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Jeyaprakashnarayanan Seenisamy, Steven L. Warner, Clifford J. Whatcott, David J. Bearss
-
Patent number: 11524052Abstract: Methods for treating neurological and other disorders, including autoimmune disorders are described. Also described is a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. Further a method is described that includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.Type: GrantFiled: December 28, 2018Date of Patent: December 13, 2022Assignee: Rush University Medical CenterInventor: Kalipada Pahan